Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study

Purpose of the article: Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks.Materials and methods: This multicenter retrospective study include...

Full description

Bibliographic Details
Main Authors: Carlo A. Vignoli, Luigi Gargiulo, Luciano Ibba, Anna Balato, Mauro Barbareschi, Stefania Barruscotti, Giulia Bazzacco, Francesco Bellinato, Vittoria G. Bianchi, Valeria Boccaletti, Raffaele D. Caposiena Caro, Silvia M. Ferrucci, Alessandro Fraghì, Elisabetta Fulgione, Giuseppe Gallo, Paolo Gisondi, Isotta Giunipero di Corteranzo, Piergiorgio Malagoli, Angelo V. Marzano, Santo R. Mercuri, Diego Orsini, Pietro Quaglino, Simone Ribero, Antonio Costanzo, Alessandra Narcisi
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Alopecia areata
baricitinib
ClinRO
JAK inhibitors
SALT
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2444494

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2024.2444494

Similar Items